Filtered By:
Condition: Heart Attack
Therapy: Cancer Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Cancers, Vol. 15, Pages 2316: Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
K. Kelly Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, ...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Tags: Review Source Type: research

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade
Biomed Pharmacother. 2021 Nov 5:112138. doi: 10.1016/j.biopha.2021.112138. Online ahead of print.ABSTRACTDiabetes mellitus (DM) is a metabolic disorder with growing global incidence, as 387 million people were diagnosed in 2014 with an expected projection of 642 million in 2040. Several complications are associated with DM including heart attack, stroke, kidney failure, blindness, and cancer. The latter is the second leading cause of death worldwide accounting for one in every six deaths, with liver, pancreas, and endometrium cancers are the most abundant among patients with diabetes. Phosphoinositide 3-kinase (PI3K)/prote...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 9, 2021 Category: Drugs & Pharmacology Authors: Agustina Dwi Retno Nurcahyanti Adeline Jap Jullietta Lady Deka Prismawan Farukh Sharopov Rachid Daoud Michael Wink Mansour Sobeh Source Type: research

Cardiac risk stratification in cancer patients: A longitudinal patient –patient network analysis
by Yuan Hou, Yadi Zhou, Muzna Hussain, G. Thomas Budd, Wai Hong Wilson Tang, James Abraham, Bo Xu, Chirag Shah, Rohit Moudgil, Zoran Popovic, Chris Watson, Leslie Cho, Mina Chung, Mohamed Kanj, Samir Kapadia, Brian Griffin, Lars Svensson, Patrick Collier, Feixiong Cheng BackgroundCardiovascular disease is a leading cause of death in general population and the second leading cause of mortality and morbidity in cancer survivors after recurrent malignancy in the United States. The growing awareness of cancer therapy –related cardiac dysfunction (CTRCD) has led to an emerging field of cardio-oncology; yet, there is limited k...
Source: PLoS Medicine - August 2, 2021 Category: Internal Medicine Authors: Yuan Hou Source Type: research

Therapeutic oxygen delivery by perfluorocarbon-based colloids
Adv Colloid Interface Sci. 2021 May 1;294:102407. doi: 10.1016/j.cis.2021.102407. Online ahead of print.ABSTRACTAfter the protocol-related indecisive clinical trial of Oxygent, a perfluorooctylbromide/phospholipid nanoemulsion, in cardiac surgery, that often unduly assigned the observed untoward effects to the product, the development of perfluorocarbon (PFC)-based O2 nanoemulsions ("blood substitutes") has come to a low. Yet, significant further demonstrations of PFC O2-delivery efficacy have continuously been reported, such as relief of hypoxia after myocardial infarction or stroke; protection of vital organs during surg...
Source: Advances in Colloid and Interface Science - June 13, 2021 Category: Chemistry Authors: Marie Pierre Krafft Jean G Riess Source Type: research

Targeted Cancer Therapies.
Abstract Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. For example, the monoclonal antibodies trastuzumab and pertuzumab target human epidermal growth factor receptor 2 (HER2) and are used when treating HER2-positive breast cancer. Although targeted oncology has improved survival by years for some incurable cancers such as metastatic breast and lung cancer, as few as 8% of patients with advanc...
Source: American Family Physician - January 30, 2021 Category: Primary Care Authors: Smith CEP, Prasad V Tags: Am Fam Physician Source Type: research

Cardiovascular Complications of Prostate Cancer Therapy
AbstractPurpose of reviewWith treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population.Recent findingsThe degree that hormone therapy contributes to cardiovascular morbidity and mortality remains uncertain with conflicting results from large...
Source: Current Treatment Options in Cardiovascular Medicine - November 12, 2020 Category: Cardiology Source Type: research

The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection —evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology
AbstractDue to its poor capacity for regeneration, the heart is particularly sensitive to the loss of contractile cardiomyocytes. The onslaught of damage caused by ischaemia and reperfusion, occurring during an acute myocardial infarction and the subsequent reperfusion therapy, can wipe out upwards of a billion cardiomyocytes. A similar program of cell death can cause the irreversible loss of neurons in ischaemic stroke. Similar pathways of lethal cell injury can contribute to other pathologies such as left ventricular dysfunction and heart failure caused by cancer therapy. Consequently, strategies designed to protect the ...
Source: Basic Research in Cardiology - October 11, 2018 Category: Cardiology Source Type: research

Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis
Purpose of review Targeted cancer therapies have revolutionized the treatment of cancer in the past decade, but cardiovascular toxicity is a rising problem in cancer patients. Here we discuss the effects of targeted cancer therapies on atherosclerosis. Increasing the awareness of these adverse effects will promote the development of evidence-based preventive strategies in the emerging field of cardiovascular oncology. Recent findings Vascular endothelial growth factor inhibitors, immunomodulatory imide drugs, tyrosine kinase inhibitors and immune checkpoint inhibitors are successfully used as treatment for many types ...
Source: Current Opinion in Lipidology - August 31, 2018 Category: Lipidology Tags: ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS: Edited by Mohamad Navab and Menno de Winther Source Type: research

New Insights from Studies of Clonal Hematopoiesis.
Abstract Clonal hematopoiesis (CH) describes an asymptomatic expansion of blood cells descended from a single hematopoietic stem cell. Recent studies have shown that CH increases in frequency with aging, and is often driven by somatic mutations in genes that are recurrently mutated in hematologic malignancies. When CH is associated with a mutation in a leukemia-associated gene at a variant allele frequency of 0.02 or greater, it is termed "clonal hematopoiesis of indeterminate potential" (CHIP).  CHIP has a 0.5-1% risk per year of progression to hematological neoplasia, and increases both all-cause mortality and ...
Source: Clinical Cancer Research - April 27, 2018 Category: Cancer & Oncology Authors: Gibson CJ, Steensma DP Tags: Clin Cancer Res Source Type: research

New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
Conclusion Older patients with colorectal cancer are at increased risk of developing CVD and CHF. Diabetes and hypertension interact with chemotherapy to increase the risk of cardiovascular morbidity. Future studies should assess the potential for personalized therapeutic options for those with preexisting morbidities and for structured monitoring for patients with a history of exposure to chemotherapy regimens, as well as explore the management of preexisting comorbidities to address long-term cardiovascular morbidity. PMID: 29337636 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Kenzik KM, Balentine C, Richman J, Kilgore M, Bhatia S, Williams GR Tags: J Clin Oncol Source Type: research